EGFR and breast carcinoma: Osimertinib targeting epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer and intrathecal trastuzumab in HER2-positive breast cancer patients with LM have shown therapeutic efficacy with the median overall survival exceeding 13 months (6, 7).